The combination of EAI045 with cetuximab is effective against lung cancer driven by EGFR(L858R/T790M) and by EGFR(L858R/T790M/C797S) in mouse models; EAI045 or cetuximab alone had a very modest effect in the L858R/T790M mutant mice, but marked tumor regressions were observed in these mice in the combination treatment [10,13]. The gene discussed is EGFR; the disease is lung carcinoma.